CollPlant Biotechnologies (CLGN) Change in Receivables (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Change in Receivables came in at $10000.0 in Q4 2025, up 106.9% YoY from $4833.3 in Q4 2024, and up 190.91% on a QoQ basis from -$11000.0 in Q3 2025.
CollPlant Biotechnologies (CLGN) Change in Receivables (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of Change in Receivables data on file, last reported at $10000.0 in Q4 2025.
- Quarterly Change in Receivables rose 106.9% year-over-year to $10000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$146000.0 (up 2.67% YoY) and the FY2025 annual result came in at $149000.0, up 199.33% from the prior year.
- Change in Receivables climbed to $10000.0 in Q4 2025, from -$11000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $10.2 million in Q3 2023 to a low of -$9.8 million in Q2 2023.
- A 5-year average of $96176.5 and a median of $4000.0 in 2023 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2021 — Change in Receivables jumped 305.64% — and 2023, when it slumped 109200.0%.
- Tracing CLGN's Change in Receivables over 5 years: stood at $560000.0 in 2021, then sank by 53.39% to $261000.0 in 2022, then sank by 98.47% to $4000.0 in 2023, then sank by 3725.0% to -$145000.0 in 2024, then soared by 106.9% to $10000.0 in 2025.
- The last three Change in Receivables figures came in at $10000.0 (Q4 2025), -$11000.0 (Q3 2025), and -$145000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Dec 31, 2024 | -145,000.00 |
| Dec 31, 2024 | -145,000.00 |
| Sep 30, 2024 | 245,000.00 |
| Sep 30, 2024 | 245,000.00 |
| Jun 30, 2024 | -160,000.00 |
| Jun 30, 2024 | -160,000.00 |
| Mar 31, 2024 | -90,000.00 |
| Mar 31, 2024 | -90,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Sep 30, 2023 | 10.16 Mn |
| Sep 30, 2023 | 10.16 Mn |
| Jun 30, 2023 | -9.84 Mn |
| Jun 30, 2023 | -9.84 Mn |
| Mar 31, 2023 | -314,000.00 |
| Mar 31, 2023 | -314,000.00 |